Skip to main content
Fig. 1 | BMC Urology

Fig. 1

From: Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?

Fig. 1

Flowchart to show patient recruitment and data collection process for the Quality of Life Survey. The HRQoL data collection was carried out with new recruits from March 2013- November 2014. In May 2013 a list of National Health Index numbers of all patients in our Urology study database was sent to the Analytical Services of the MOH, New Zealand, to check for any recorded mortalities among patients recruited. This check was carried out subsequent to approval from the HDEC, the MOH, New Zealand (ethics reference NTY/05/06/037/AM02). In November 2013, upon receiving this information from the Analytical Services of the MOH, all PC survivors in our patient cohort who have not yet completed the PC treatment/HRQoL survey, were invited to take part. Therefore, the final number of patients that took part in this survey was dependent on patient response to these invitations. (*Number assumed to have received the invitation includes PC survivors who completed the survey, those that declined and those assumed to have received the invitation.)

Back to article page